Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Exclusive | Secrets behind Tyler Robinson's lucrative family business revealed — as Utah taxpayers foot $10M legal bills for Charlie Kirk's alleged killer